An observational study in Depressive Disorder, sponsored by Haukeland University Hospital. Recruiting at 2 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-26.
Sponsored by Haukeland University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Depressive Disorder with a site in Norway — 4 open to participants now, 5 under way, none of them phase 3. Depressive Disorder · Norway.
Among the 15 studies in Depressive Disorder with a site in Norway, this one is one of 3 that started in 2013, is one of 5 observational ones, and was the 12th registered.
857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.
Browse Depressive Disorder studies →4 of the 15 studies in Depressive Disorder with a site in Norway are open now. Recruiting first, the newest first:
University Hospital of North Norway · Sites in Norway
Ages 22–65
Oslo University Hospital · Sites in Norway
Ages 13–18
University of Oslo · Sites in Norway
Ages 18–65
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2013.
This study's planned enrollment of 600 is above the median of 174 across 140 observational studies indexed under Depressive Disorder.
Median enrollment 52 across the 10 interventional studies, 200 across the 5 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 10 most frequent:
Haukeland University Hospital is the lead sponsor of 284 studies on the registry; 58 are open to participants now.
Haukeland University Hospital has 1 study filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Depressive Disorder with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The overall aim of the current project is to assess the acute and long term outcome of ECT (both patient and clinician rated) in a non-selected patient cohort from ordinary clinical activity, and to seek out factors predicting response and remission, side effects and relapse.
Patients reffered to electroconvulsive ECT are (after written consent) enroled in a research registry. Based on (clinician and patient rated) measures of depressive symptoms and overall cognitive function, the short and long-term (6 months) efficacy of ECT will be described, and factors predicting response and relapse identified.
The duration of possible cognitive impairment and factors predicting cognitive outcome will be examined.
population based cohort from ordinary clinical activity
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
electroconvulsive therapy
Change of Montgomery and Åsberg Depression Rating Scale (MADRS) score from pretreatment at posttreatment; MADRS range 0 - 60, with higher scores indicating more severe depression)
depressive symptoms
Time frame: up to 8 weeks
Change of Mini Mental State Examination (MMSE-NR) score from pretreatment at posttreatment; MMS-E range 0-30 with lower scores indicating more severe cognitive impairment
overall cognitive function
Time frame: up to 8 weeks
Change of Beck depression inventory (BDI) score from pretreatment at posttreatment; BDI range 0-63, with higher scores indicating more severe depression
depressive symptoms, patient rated
Time frame: up to 8 weeks
Change of Everyday Memory Questionnaire (EMQ) score from pretreatment at posttreatment with higher scores indicating more severe impairment
overall subjective cognitive function, patient rated
Time frame: up to 8 weeks
Change of Patient rated improvement (PGI) score from pretreatment at posttreatment
Likert scale
Time frame: up to 8 weeks
Change of Clinical Global Impression (CGI) score from pretreatment at posttreatment
Likert scale
Time frame: up to 8 weeks
Change of Subjective cognitive function score from pretreatment at posttreatment
Likert scale
Time frame: up to 8 weeks
Change of Montgomery and Åsberg Depression Rating Scale (MADRS) score from pretreatment at follow up, MADRS range 0 - 60, with higher scores indicating more severe depression)
depressive symptoms
Time frame: 6 months
Change of Mini Mental State Examination (MMSE-NR) score from pretreatment at follow up, MMS-E range 0-30 with lower scores indicating more severe cognitive impairment
overall cognitive function
Time frame: 6 months
Change of Beck depression inventory (BDI) score from pretreatment at follow up, BDI range 0-63, with higher scores indicating more severe depression
depressive symptoms, patient rated
Time frame: 6 months
Change of Everyday Memory Questionnaire (EMQ) score from pretreatment at follow up
overall subjective cognitive function, patient rated
Time frame: 6 months
Change of Patient rated improvement (PGI) score from pretreatment at follow up
Likert scale
Time frame: 6 months
Change of Clinical Global Impression scale (CGI) from pretreatment at follow up
Likert scale
Time frame: 6 months
Plan to share: Undecided — after approval from data protection manager IPD will be shared on reasonable request
No publications or documents are linked to this record.
Started Mar 2013 (actual). Primary completion is estimated for Dec 2028, 189 months after the start.
Of 54 non-industry observational studies under Depressive Disorder, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 104. This study's planned 189 months is above that.
Counting every sponsor, half of 57 studies reached it within 38 months; a quarter within 21 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haukeland University Hospital →